KDNY — Chinook Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.90bn
- $2.60bn
- $6.13m
Annual income statement for Chinook Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.1 | 17.3 | 0.827 | 51.6 | 6.13 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 116 | 107 | 84.8 | 151 | 191 |
| Operating Profit | -101 | -90.1 | -83.9 | -99 | -185 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -96.1 | -84.8 | -83.6 | -101 | -184 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -95.4 | -82.4 | -81.6 | -103 | -188 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -95.4 | -82.4 | -81.6 | -103 | -188 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -95.4 | -82.4 | -81.6 | -103 | -188 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.88 | -4.89 | -4.83 | -2.36 | -2.92 |